Kit to Aid Disease Biomarker Discovery

The high-density antibody affinity media enhance the ability to visualize low-abundance proteins in the plasma proteome using standard analysis technology. The kit answers a major challenge facing scientists in clinical proteomics: the inability to detect the majority of low-abundance proteins in plasma, which are the mediators of disease or drug efficacy. The ProteoPrep 20 kit was introduced by Sigma, a division of Sigma-Aldrich Corp. (St. Louis, MO, USA).

In addition, the multivalent antibody resin utilizes novel recombinant antibodies that allow for a significantly higher density of conjugation and, hence, efficiency of depletion
with minimal sample loss or dilution. Sigma developed the technology in cooperation with leading scientists in proteomics and through knowledge gained while participating in the Human Proteome Organization (HUPO) Plasma Proteome Project (Montreal, Canada).

"The innovative depletion technology greatly enables deeper penetration into the plasma proteome and will facilitate the discovery of new potential biomarkers in cancer research and many other areas, using proteome analysis,” said Michael Pisano, president and co-founder of Proteomic Research Services (Ann Arbor, MI, USA), a proteomics services company. "We have been able to show that after depletion with the ProteoPrep 20 kit, proteins can be identified that were previously not detected from either whole plasma or following depletion with standard tools.”




Related Links:
Sigma-Aldrich